Search

Your search keyword '"Avigan, David E"' showing total 316 results
Start Over Author "Avigan, David E"
316 results on '"Avigan, David E"'

2. Cellular and Vaccine-Based Immunotherapy for Hematologic Malignancies

Author

Avigan, Zachary M., Boussi, Leora S., Avigan, David E., Rezaei, Nima, Series Editor, Aguiar, Rodrigo, Editorial Board Member, Ahmed, Atif A., Editorial Board Member, Ambrosio, Maria R., Editorial Board Member, Artac, Mehmet, Editorial Board Member, Augustine, Tanya N., Editorial Board Member, Bambauer, Rolf, Editorial Board Member, Bhat, Ajaz Ahmad, Editorial Board Member, Bertolaccini, Luca, Editorial Board Member, Bianchini, Chiara, Editorial Board Member, Cavic, Milena, Editorial Board Member, Chakrabarti, Sakti, Editorial Board Member, Cho, William C. S., Editorial Board Member, Czarnecka, Anna M., Editorial Board Member, Domingues, Cátia, Editorial Board Member, Eşkazan, A. Emre, Editorial Board Member, Fares, Jawad, Editorial Board Member, Fonseca Alves, Carlos E., Editorial Board Member, Fru, Pascaline, Editorial Board Member, Da Gama Duarte, Jessica, Editorial Board Member, García, Mónica C., Editorial Board Member, Gener, Melissa A.H., Editorial Board Member, Estrada Guadarrama, José Antonio, Editorial Board Member, Hargadon, Kristian M., Editorial Board Member, Holvoet, Paul, Editorial Board Member, Jurisic, Vladimir, Editorial Board Member, Kabir, Yearul, Editorial Board Member, Katsila, Theodora, Editorial Board Member, Kleeff, Jorg, Editorial Board Member, Liang, Chao, Editorial Board Member, Tan, Mei Lan, Editorial Board Member, Li, Weijie, Editorial Board Member, Prado López, Sonia, Editorial Board Member, Macha, Muzafar A., Editorial Board Member, Malara, Natalia, Editorial Board Member, Orhan, Adile, Editorial Board Member, Prado-Garcia, Heriberto, Editorial Board Member, Pérez-Velázquez, Judith, Editorial Board Member, Rashed, Wafaa M., Editorial Board Member, Sanguedolce, Francesca, Editorial Board Member, Sorrentino, Rosalinda, Editorial Board Member, Shubina, Irina Zh., Editorial Board Member, de Araujo, Heloisa Sobreiro Selistre, Editorial Board Member, Torres-Suárez, Ana Isabel, Editorial Board Member, Włodarczyk, Jakub, Editorial Board Member, Yeong, Joe Poh Sheng, Editorial Board Member, Toscano, Marta A., Editorial Board Member, Wong, Tak-Wah, Editorial Board Member, Yin, Jun, Editorial Board Member, Yu, Bin, Editorial Board Member, and Hamdy, Nadia M., Editorial Board Member

Published
2024
Full Text
View/download PDF

3. Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma

Author

Liau, Linda M, Ashkan, Keyoumars, Brem, Steven, Campian, Jian L, Trusheim, John E, Iwamoto, Fabio M, Tran, David D, Ansstas, George, Cobbs, Charles S, Heth, Jason A, Salacz, Michael E, D’Andre, Stacy, Aiken, Robert D, Moshel, Yaron A, Nam, Joo Y, Pillainayagam, Clement P, Wagner, Stephanie A, Walter, Kevin A, Chaudhary, Rekha, Goldlust, Samuel A, Lee, Ian Y, Bota, Daniela A, Elinzano, Heinrich, Grewal, Jai, Lillehei, Kevin, Mikkelsen, Tom, Walbert, Tobias, Abram, Steven, Brenner, Andrew J, Ewend, Matthew G, Khagi, Simon, Lovick, Darren S, Portnow, Jana, Kim, Lyndon, Loudon, William G, Martinez, Nina L, Thompson, Reid C, Avigan, David E, Fink, Karen L, Geoffroy, Francois J, Giglio, Pierre, Gligich, Oleg, Krex, Dietmar, Lindhorst, Scott M, Lutzky, Jose, Meisel, Hans-Jörg, Nadji-Ohl, Minou, Sanchin, Lhagva, Sloan, Andrew, Taylor, Lynne P, Wu, Julian K, Dunbar, Erin M, Etame, Arnold B, Kesari, Santosh, Mathieu, David, Piccioni, David E, Baskin, David S, Lacroix, Michel, May, Sven-Axel, New, Pamela Z, Pluard, Timothy J, Toms, Steven A, Tse, Victor, Peak, Scott, Villano, John L, Battiste, James D, Mulholland, Paul J, Pearlman, Michael L, Petrecca, Kevin, Schulder, Michael, Prins, Robert M, Boynton, Alton L, and Bosch, Marnix L

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Prevention, Brain Disorders, Clinical Trials and Supportive Activities, Rare Diseases, Neurosciences, Clinical Research, Cancer, Brain Cancer, 6.1 Pharmaceuticals, Humans, Glioblastoma, Temozolomide, Prospective Studies, Brain Neoplasms, Recurrence, Dendritic Cells, Vaccination, Public Health and Health Services, Oncology and carcinogenesis
Abstract

ImportanceGlioblastoma is the most lethal primary brain cancer. Clinical outcomes for glioblastoma remain poor, and new treatments are needed.ObjectiveTo investigate whether adding autologous tumor lysate-loaded dendritic cell vaccine (DCVax-L) to standard of care (SOC) extends survival among patients with glioblastoma.Design, setting, and participantsThis phase 3, prospective, externally controlled nonrandomized trial compared overall survival (OS) in patients with newly diagnosed glioblastoma (nGBM) and recurrent glioblastoma (rGBM) treated with DCVax-L plus SOC vs contemporaneous matched external control patients treated with SOC. This international, multicenter trial was conducted at 94 sites in 4 countries from August 2007 to November 2015. Data analysis was conducted from October 2020 to September 2021.InterventionsThe active treatment was DCVax-L plus SOC temozolomide. The nGBM external control patients received SOC temozolomide and placebo; the rGBM external controls received approved rGBM therapies.Main outcomes and measuresThe primary and secondary end points compared overall survival (OS) in nGBM and rGBM, respectively, with contemporaneous matched external control populations from the control groups of other formal randomized clinical trials.ResultsA total of 331 patients were enrolled in the trial, with 232 randomized to the DCVax-L group and 99 to the placebo group. Median OS (mOS) for the 232 patients with nGBM receiving DCVax-L was 19.3 (95% CI, 17.5-21.3) months from randomization (22.4 months from surgery) vs 16.5 (95% CI, 16.0-17.5) months from randomization in control patients (HR = 0.80; 98% CI, 0.00-0.94; P = .002). Survival at 48 months from randomization was 15.7% vs 9.9%, and at 60 months, it was 13.0% vs 5.7%. For 64 patients with rGBM receiving DCVax-L, mOS was 13.2 (95% CI, 9.7-16.8) months from relapse vs 7.8 (95% CI, 7.2-8.2) months among control patients (HR, 0.58; 98% CI, 0.00-0.76; P

Published
2023

4. Cross center single-cell RNA sequencing study of the immune microenvironment in rapid progressing multiple myeloma

Author

Pilcher, William, Thomas, Beena E., Bhasin, Swati S., Jayasinghe, Reyka G., Yao, Lijun, Gonzalez-Kozlova, Edgar, Dasari, Surendra, Kim-Schulze, Seunghee, Rahman, Adeeb, Patton, Jonathan, Fiala, Mark, Cheloni, Giulia, Kourelis, Taxiarchis, Dhodapkar, Madhav V., Vij, Ravi, Mehr, Shaadi, Hamilton, Mark, Cho, Hearn Jay, Auclair, Daniel, Avigan, David E., Kumar, Shaji K., Gnjatic, Sacha, Ding, Li, and Bhasin, Manoj

Published
2023
Full Text
View/download PDF

6. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma

Author

Shah, Nina, Aiello, Jack, Avigan, David E, Berdeja, Jesus G, Borrello, Ivan M, Chari, Ajai, Cohen, Adam D, Ganapathi, Karthik, Gray, Lissa, Green, Damian, Krishnan, Amrita, Lin, Yi, Manasanch, Elisabet, Munshi, Nikhil C, Nooka, Ajay K, Rapoport, Aaron P, Smith, Eric L, Vij, Ravi, and Dhodapkar, Madhav

Subjects
Hematology, Immunization, Rare Diseases, Vaccine Related, Biotechnology, Cancer, Orphan Drug, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Consensus, Humans, Immunotherapy, Multiple Myeloma, guidelines as topic, immunotherapy, hematological neoplasms, receptors, chimeric antigen, antineoplastic protocols, receptors, chimeric antigen
Abstract

Outcomes in multiple myeloma (MM) have improved dramatically in the last two decades with the advent of novel therapies including immunomodulatory agents (IMiDs), proteasome inhibitors and monoclonal antibodies. In recent years, immunotherapy for the treatment of MM has advanced rapidly, with the approval of new targeted agents and monoclonal antibodies directed against myeloma cell-surface antigens, as well as maturing data from late stage trials of chimeric antigen receptor CAR T cells. Therapies that engage the immune system to treat myeloma offer significant clinical benefits with durable responses and manageable toxicity profiles, however, the appropriate use of these immunotherapy agents can present unique challenges for practicing physicians. Therefore, the Society for Immunotherapy of Cancer convened an expert panel, which met to consider the current role of approved and emerging immunotherapy agents in MM and provide guidance to the oncology community by developing consensus recommendations. As immunotherapy evolves as a therapeutic option for the treatment of MM, these guidelines will be updated.

Published
2020

7. Phase 2 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease

Author

Koshy, Anita G., Kim, Haesook T., Liegel, Jessica, Arnason, Jon, Ho, Vincent T., Antin, Joseph H., Joyce, Robin, Cutler, Corey, Gooptu, Mahasweta, Nikiforow, Sarah, Logan, Emma K., Elavalakanar, Pavania, Narcis, Michele, Stroopinsky, Dina, Avigan, Zachary M., Boussi, Leora, Stephenson, Susan, El Banna, Hassan, Bindal, Poorva, Cheloni, Giulia, Avigan, David E., Soiffer, Robert J., and Rosenblatt, Jacalyn

Published
2023
Full Text
View/download PDF

11. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma

Author

Liau, Linda M, Ashkan, Keyoumars, Tran, David D, Campian, Jian L, Trusheim, John E, Cobbs, Charles S, Heth, Jason A, Salacz, Michael, Taylor, Sarah, D’Andre, Stacy D, Iwamoto, Fabio M, Dropcho, Edward J, Moshel, Yaron A, Walter, Kevin A, Pillainayagam, Clement P, Aiken, Robert, Chaudhary, Rekha, Goldlust, Samuel A, Bota, Daniela A, Duic, Paul, Grewal, Jai, Elinzano, Heinrich, Toms, Steven A, Lillehei, Kevin O, Mikkelsen, Tom, Walbert, Tobias, Abram, Steven R, Brenner, Andrew J, Brem, Steven, Ewend, Matthew G, Khagi, Simon, Portnow, Jana, Kim, Lyndon J, Loudon, William G, Thompson, Reid C, Avigan, David E, Fink, Karen L, Geoffroy, Francois J, Lindhorst, Scott, Lutzky, Jose, Sloan, Andrew E, Schackert, Gabriele, Krex, Dietmar, Meisel, Hans-Jorg, Wu, Julian, Davis, Raphael P, Duma, Christopher, Etame, Arnold B, Mathieu, David, Kesari, Santosh, Piccioni, David, Westphal, Manfred, Baskin, David S, New, Pamela Z, Lacroix, Michel, May, Sven-Axel, Pluard, Timothy J, Tse, Victor, Green, Richard M, Villano, John L, Pearlman, Michael, Petrecca, Kevin, Schulder, Michael, Taylor, Lynne P, Maida, Anthony E, Prins, Robert M, Cloughesy, Timothy F, Mulholland, Paul, and Bosch, Marnix L

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Immunology, Prevention, Orphan Drug, Clinical Research, Vaccine Related, Rare Diseases, Immunization, Neurosciences, Brain Disorders, Cancer, Clinical Trials and Supportive Activities, Brain Cancer, Patient Safety, 6.1 Pharmaceuticals, Adult, Aged, Brain Neoplasms, Cancer Vaccines, Dendritic Cells, Endpoint Determination, Female, Glioblastoma, Humans, Male, Middle Aged, Prognosis, Survival Analysis, Treatment Outcome, Young Adult, Immunotherapy, Dendritic cell, Vaccine, Medical and Health Sciences, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundStandard therapy for glioblastoma includes surgery, radiotherapy, and temozolomide. This Phase 3 trial evaluates the addition of an autologous tumor lysate-pulsed dendritic cell vaccine (DCVax®-L) to standard therapy for newly diagnosed glioblastoma.MethodsAfter surgery and chemoradiotherapy, patients were randomized (2:1) to receive temozolomide plus DCVax-L (n = 232) or temozolomide and placebo (n = 99). Following recurrence, all patients were allowed to receive DCVax-L, without unblinding. The primary endpoint was progression free survival (PFS); the secondary endpoint was overall survival (OS).ResultsFor the intent-to-treat (ITT) population (n = 331), median OS (mOS) was 23.1 months from surgery. Because of the cross-over trial design, nearly 90% of the ITT population received DCVax-L. For patients with methylated MGMT (n = 131), mOS was 34.7 months from surgery, with a 3-year survival of 46.4%. As of this analysis, 223 patients are ≥ 30 months past their surgery date; 67 of these (30.0%) have lived ≥ 30 months and have a Kaplan-Meier (KM)-derived mOS of 46.5 months. 182 patients are ≥ 36 months past surgery; 44 of these (24.2%) have lived ≥ 36 months and have a KM-derived mOS of 88.2 months. A population of extended survivors (n = 100) with mOS of 40.5 months, not explained by known prognostic factors, will be analyzed further. Only 2.1% of ITT patients (n = 7) had a grade 3 or 4 adverse event that was deemed at least possibly related to the vaccine. Overall adverse events with DCVax were comparable to standard therapy alone.ConclusionsAddition of DCVax-L to standard therapy is feasible and safe in glioblastoma patients, and may extend survival. Trial registration Funded by Northwest Biotherapeutics; Clinicaltrials.gov number: NCT00045968; https://clinicaltrials.gov/ct2/show/NCT00045968?term=NCT00045968&rank=1 ; initially registered 19 September 2002.

Published
2018

12. Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma

Author

Liau, Linda M, Ashkan, Keyoumars, Tran, David D, Campian, Jian L, Trusheim, John E, Cobbs, Charles S, Heth, Jason A, Salacz, Michael, Taylor, Sarah, D’Andre, Stacy D, Iwamoto, Fabio M, Dropcho, Edward J, Moshel, Yaron A, Walter, Kevin A, Pillainayagam, Clement P, Aiken, Robert, Chaudhary, Rekha, Goldlust, Samuel A, Bota, Daniela A, Duic, Paul, Grewal, Jai, Elinzano, Heinrich, Toms, Steven A, Lillehei, Kevin O, Mikkelsen, Tom, Walbert, Tobias, Abram, Steven R, Brenner, Andrew J, Brem, Steven, Ewend, Matthew G, Khagi, Simon, Portnow, Jana, Kim, Lyndon J, Loudon, William G, Thompson, Reid C, Avigan, David E, Fink, Karen L, Geoffroy, Francois J, Lindhorst, Scott, Lutzky, Jose, Sloan, Andrew E, Schackert, Gabriele, Krex, Dietmar, Meisel, Hans-Jorg, Wu, Julian, Davis, Raphael P, Duma, Christopher, Etame, Arnold B, Mathieu, David, Kesari, Santosh, Piccioni, David, Westphal, Manfred, Baskin, David S, New, Pamela Z, Lacroix, Michel, May, Sven-Axel, Pluard, Timothy J, Tse, Victor, Green, Richard M, Villano, John L, Pearlman, Michael, Petrecca, Kevin, Schulder, Michael, Taylor, Lynne P, Maida, Anthony E, Prins, Robert M, Cloughesy, Timothy F, Mulholland, Paul, and Bosch, Marnix L

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Rare Diseases, Brain Disorders, Neurosciences, Medical and Health Sciences, Immunology, Biomedical and clinical sciences, Health sciences
Abstract

Following publication of the original article [1], the authors reported an error in the spelling of one of the author names. In this Correction the incorrect and correct author names are indicated and the author name has been updated in the original publication. The authors also reported an error in the Methods section of the original article. In this Correction the incorrect and correct versions of the affected sentence are indicated. The original article has not been updated with regards to the error in the Methods section.

Published
2018

14. High CD34‐positive cell dose in matched unrelated donor allogeneic hematopoietic stem cell transplant is not associated with graft‐versus‐host disease or mortality.

Author

Avigan, Zachary M., Dias, Ajoy L., Dodge, Laura E., Arnason, Jon E., Joyce, Robin M., Liegel, Jessica, Rosenblatt, Jacalyn, Weinstock, Matthew J., Avigan, David E., and Haspel, Richard L.

Subjects
STEM cell transplantation, HEMATOPOIETIC stem cell transplantation, HEMATOPOIETIC stem cells, GRAFT versus host disease, CD34 antigen, STEM cells, T cells
Abstract

Background: CD34+ stem cells serve as the primary graft source for allogeneic transplants, with a minimum of 2–4 × 106 cells/kg needed for engraftment. There are conflicting data on outcomes at high stem cell doses, with studies limited by few patients receiving doses far above the minimum target. Study design and Methods: In this retrospective, single‐center study of patients with hematologic malignancies who underwent matched unrelated donor transplants, we assessed outcomes for engraftment, survival, relapse, and graft‐versus‐host disease (GVHD) for the highest CD34+ dose quintile (>13 × 106 cells/kg, n = 36) compared to the remaining patients (n = 139). Similar analysis was performed correlating T cell dose and outcomes. Results: There was no difference between the groups in neutrophil engraftment, with a trend toward faster platelet engraftment. There was no significant difference in mortality (adjusted risk ratio [aRR] = 1.02, 95% confidence interval [CI] = 0.85–1.22), relapse (aRR = 1.10, 95% CI = 0.85–1.42), or overall survival by Kaplan–Meier analysis (p =.44). High CD34+ dose was not associated with higher incidence of acute GVHD (aRR = 0.99 grades II–IV, aRR = 1.18 grades III–IV) or chronic GVHD (aRR = 0.87 overall, RR = 1.21 severe). There was limited correlation between CD34+ and T cell dose (R2 =.073), and there was no significant difference in survival, relapse, or GVHD in the highest T cell dose quintile (n = 33) compared to the remaining quintiles (n = 132). Discussion: We found no difference in survival, relapse, or GVHD incidence or severity in patients receiving CD34+ doses above prior cutoffs reported in the literature. These data do not support the routine use of graft CD34+ dose reduction. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease

Author

Nahas, Myrna R., Soiffer, Robert J., Kim, Haesook T., Alyea, Edwin P., III, Arnason, Jon, Joyce, Robin, Antin, Joseph H., Ho, Vincent T., Stroopinsky, Dina, Li, Shuli, Levine, James D., McMasters, Malgorzata, Jain, Salvia, Hamdan, Ayad, Tzachanis, Dimitrios, Bryant, Mary Paty, Logan, Emma K., Bazemore, Josie, Stewart, Jeremy, Joyce, Amy, Stephenson, Susan, Washington, Abigail, Cole, Leandra, Pyzer, Athalia, Leaf, Rebecca Karp, Avigan, David E., and Rosenblatt, Jacalyn

Published
2018
Full Text
View/download PDF

16. Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial

Author

Armand, Philippe, Nagler, Arnon, Weller, Edie A, Devine, Steven M, Avigan, David E, Chen, Yi-Bin, Kaminski, Mark S, Holland, H Kent, Winter, Jane N, Mason, James R, Fay, Joseph W, Rizzieri, David A, Hosing, Chitra M, Ball, Edward D, Uberti, Joseph P, Lazarus, Hillard M, Mapara, Markus Y, Gregory, Stephanie A, Timmerman, John M, Andorsky, David, Or, Reuven, Waller, Edmund K, Rotem-Yehudar, Rinat, and Gordon, Leo I

Subjects
Rare Diseases, Cancer, Hematology, Biotechnology, Transplantation, Clinical Research, Stem Cell Research, Lymphoma, Prevention, Evaluation of treatments and therapeutic interventions, 6.2 Cellular and gene therapies, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Chile, Combined Modality Therapy, Disease-Free Survival, Drug Administration Schedule, Fatigue, Female, Hematopoietic Stem Cell Transplantation, Humans, Immune Tolerance, India, Israel, Lymphocyte Count, Lymphoma, Large B-Cell, Diffuse, Male, Middle Aged, Neutropenia, Programmed Cell Death 1 Receptor, Transplantation, Autologous, Treatment Outcome, United States, Young Adult, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeThe Programmed Death-1 (PD-1) immune checkpoint pathway may be usurped by tumors, including diffuse large B-cell lymphoma (DLBCL), to evade immune surveillance. The reconstituting immune landscape after autologous hematopoietic stem-cell transplantation (AHSCT) may be particularly favorable for breaking immune tolerance through PD-1 blockade.Patients and methodsWe conducted an international phase II study of pidilizumab, an anti-PD-1 monoclonal antibody, in patients with DLBCL undergoing AHSCT, with correlative studies of lymphocyte subsets. Patients received three doses of pidilizumab beginning 1 to 3 months after AHSCT.ResultsSixty-six eligible patients were treated. Toxicity was mild. At 16 months after the first treatment, progression-free survival (PFS) was 0.72 (90% CI, 0.60 to 0.82), meeting the primary end point. Among the 24 high-risk patients who remained positive on positron emission tomography after salvage chemotherapy, the 16-month PFS was 0.70 (90% CI, 0.51 to 0.82). Among the 35 patients with measurable disease after AHSCT, the overall response rate after pidilizumab treatment was 51%. Treatment was associated with increases in circulating lymphocyte subsets including PD-L1E-bearing lymphocytes, suggesting an on-target in vivo effect of pidilizumab.ConclusionThis is the first demonstration of clinical activity of PD-1 blockade in DLBCL. Given these results, PD-1 blockade after AHSCT using pidilizumab may represent a promising therapeutic strategy in this disease.

Published
2013

18. Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.

Author

Liau, Linda M, Liau, Linda M, Ashkan, Keyoumars, Brem, Steven, Campian, Jian L, Trusheim, John E, Iwamoto, Fabio M, Tran, David D, Ansstas, George, Cobbs, Charles S, Heth, Jason A, Salacz, Michael E, D'Andre, Stacy, Aiken, Robert D, Moshel, Yaron A, Nam, Joo Y, Pillainayagam, Clement P, Wagner, Stephanie A, Walter, Kevin A, Chaudhary, Rekha, Goldlust, Samuel A, Lee, Ian Y, Bota, Daniela A, Elinzano, Heinrich, Grewal, Jai, Lillehei, Kevin, Mikkelsen, Tom, Walbert, Tobias, Abram, Steven, Brenner, Andrew J, Ewend, Matthew G, Khagi, Simon, Lovick, Darren S, Portnow, Jana, Kim, Lyndon, Loudon, William G, Martinez, Nina L, Thompson, Reid C, Avigan, David E, Fink, Karen L, Geoffroy, Francois J, Giglio, Pierre, Gligich, Oleg, Krex, Dietmar, Lindhorst, Scott M, Lutzky, Jose, Meisel, Hans-Jörg, Nadji-Ohl, Minou, Sanchin, Lhagva, Sloan, Andrew, Taylor, Lynne P, Wu, Julian K, Dunbar, Erin M, Etame, Arnold B, Kesari, Santosh, Mathieu, David, Piccioni, David E, Baskin, David S, Lacroix, Michel, May, Sven-Axel, New, Pamela Z, Pluard, Timothy J, Toms, Steven A, Tse, Victor, Peak, Scott, Villano, John L, Battiste, James D, Mulholland, Paul J, Pearlman, Michael L, Petrecca, Kevin, Schulder, Michael, Prins, Robert M, Boynton, Alton L, Bosch, Marnix L, Liau, Linda M, Liau, Linda M, Ashkan, Keyoumars, Brem, Steven, Campian, Jian L, Trusheim, John E, Iwamoto, Fabio M, Tran, David D, Ansstas, George, Cobbs, Charles S, Heth, Jason A, Salacz, Michael E, D'Andre, Stacy, Aiken, Robert D, Moshel, Yaron A, Nam, Joo Y, Pillainayagam, Clement P, Wagner, Stephanie A, Walter, Kevin A, Chaudhary, Rekha, Goldlust, Samuel A, Lee, Ian Y, Bota, Daniela A, Elinzano, Heinrich, Grewal, Jai, Lillehei, Kevin, Mikkelsen, Tom, Walbert, Tobias, Abram, Steven, Brenner, Andrew J, Ewend, Matthew G, Khagi, Simon, Lovick, Darren S, Portnow, Jana, Kim, Lyndon, Loudon, William G, Martinez, Nina L, Thompson, Reid C, Avigan, David E, Fink, Karen L, Geoffroy, Francois J, Giglio, Pierre, Gligich, Oleg, Krex, Dietmar, Lindhorst, Scott M, Lutzky, Jose, Meisel, Hans-Jörg, Nadji-Ohl, Minou, Sanchin, Lhagva, Sloan, Andrew, Taylor, Lynne P, Wu, Julian K, Dunbar, Erin M, Etame, Arnold B, Kesari, Santosh, Mathieu, David, Piccioni, David E, Baskin, David S, Lacroix, Michel, May, Sven-Axel, New, Pamela Z, Pluard, Timothy J, Toms, Steven A, Tse, Victor, Peak, Scott, Villano, John L, Battiste, James D, Mulholland, Paul J, Pearlman, Michael L, Petrecca, Kevin, Schulder, Michael, Prins, Robert M, Boynton, Alton L, and Bosch, Marnix L

Abstract

ImportanceGlioblastoma is the most lethal primary brain cancer. Clinical outcomes for glioblastoma remain poor, and new treatments are needed.ObjectiveTo investigate whether adding autologous tumor lysate-loaded dendritic cell vaccine (DCVax-L) to standard of care (SOC) extends survival among patients with glioblastoma.Design, setting, and participantsThis phase 3, prospective, externally controlled nonrandomized trial compared overall survival (OS) in patients with newly diagnosed glioblastoma (nGBM) and recurrent glioblastoma (rGBM) treated with DCVax-L plus SOC vs contemporaneous matched external control patients treated with SOC. This international, multicenter trial was conducted at 94 sites in 4 countries from August 2007 to November 2015. Data analysis was conducted from October 2020 to September 2021.InterventionsThe active treatment was DCVax-L plus SOC temozolomide. The nGBM external control patients received SOC temozolomide and placebo; the rGBM external controls received approved rGBM therapies.Main outcomes and measuresThe primary and secondary end points compared overall survival (OS) in nGBM and rGBM, respectively, with contemporaneous matched external control populations from the control groups of other formal randomized clinical trials.ResultsA total of 331 patients were enrolled in the trial, with 232 randomized to the DCVax-L group and 99 to the placebo group. Median OS (mOS) for the 232 patients with nGBM receiving DCVax-L was 19.3 (95% CI, 17.5-21.3) months from randomization (22.4 months from surgery) vs 16.5 (95% CI, 16.0-17.5) months from randomization in control patients (HR = 0.80; 98% CI, 0.00-0.94; P = .002). Survival at 48 months from randomization was 15.7% vs 9.9%, and at 60 months, it was 13.0% vs 5.7%. For 64 patients with rGBM receiving DCVax-L, mOS was 13.2 (95% CI, 9.7-16.8) months from relapse vs 7.8 (95% CI, 7.2-8.2) months among control patients (HR, 0.58; 98% CI, 0.00-0.76; P < .001). Survival at 24 and 30 months after rec

Published
2023

19. Data from Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity

Author

Patnaik, Akash, primary, Swanson, Kenneth D., primary, Csizmadia, Eva, primary, Solanki, Aniruddh, primary, Landon-Brace, Natalie, primary, Gehring, Marina P., primary, Helenius, Katja, primary, Olson, Brian M., primary, Pyzer, Athalia R., primary, Wang, Lily C., primary, Elemento, Olivier, primary, Novak, Jesse, primary, Thornley, Thomas B., primary, Asara, John M., primary, Montaser, Laleh, primary, Timmons, Joshua J., primary, Morgan, Todd M., primary, Wang, Yugang, primary, Levantini, Elena, primary, Clohessy, John G., primary, Kelly, Kathleen, primary, Pandolfi, Pier Paolo, primary, Rosenblatt, Jacalyn M., primary, Avigan, David E., primary, Ye, Huihui, primary, Karp, Jeffrey M., primary, Signoretti, Sabina, primary, Balk, Steven P., primary, and Cantley, Lewis C., primary

Published
2023
Full Text
View/download PDF

20. Supplementary Figure Legends from Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity

Author

Patnaik, Akash, primary, Swanson, Kenneth D., primary, Csizmadia, Eva, primary, Solanki, Aniruddh, primary, Landon-Brace, Natalie, primary, Gehring, Marina P., primary, Helenius, Katja, primary, Olson, Brian M., primary, Pyzer, Athalia R., primary, Wang, Lily C., primary, Elemento, Olivier, primary, Novak, Jesse, primary, Thornley, Thomas B., primary, Asara, John M., primary, Montaser, Laleh, primary, Timmons, Joshua J., primary, Morgan, Todd M., primary, Wang, Yugang, primary, Levantini, Elena, primary, Clohessy, John G., primary, Kelly, Kathleen, primary, Pandolfi, Pier Paolo, primary, Rosenblatt, Jacalyn M., primary, Avigan, David E., primary, Ye, Huihui, primary, Karp, Jeffrey M., primary, Signoretti, Sabina, primary, Balk, Steven P., primary, and Cantley, Lewis C., primary

Published
2023
Full Text
View/download PDF

21. Supplementary Figure 1 from Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity

Author

Patnaik, Akash, primary, Swanson, Kenneth D., primary, Csizmadia, Eva, primary, Solanki, Aniruddh, primary, Landon-Brace, Natalie, primary, Gehring, Marina P., primary, Helenius, Katja, primary, Olson, Brian M., primary, Pyzer, Athalia R., primary, Wang, Lily C., primary, Elemento, Olivier, primary, Novak, Jesse, primary, Thornley, Thomas B., primary, Asara, John M., primary, Montaser, Laleh, primary, Timmons, Joshua J., primary, Morgan, Todd M., primary, Wang, Yugang, primary, Levantini, Elena, primary, Clohessy, John G., primary, Kelly, Kathleen, primary, Pandolfi, Pier Paolo, primary, Rosenblatt, Jacalyn M., primary, Avigan, David E., primary, Ye, Huihui, primary, Karp, Jeffrey M., primary, Signoretti, Sabina, primary, Balk, Steven P., primary, and Cantley, Lewis C., primary

Published
2023
Full Text
View/download PDF

22. Supplementary Figure 5 from Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity

Author

Patnaik, Akash, primary, Swanson, Kenneth D., primary, Csizmadia, Eva, primary, Solanki, Aniruddh, primary, Landon-Brace, Natalie, primary, Gehring, Marina P., primary, Helenius, Katja, primary, Olson, Brian M., primary, Pyzer, Athalia R., primary, Wang, Lily C., primary, Elemento, Olivier, primary, Novak, Jesse, primary, Thornley, Thomas B., primary, Asara, John M., primary, Montaser, Laleh, primary, Timmons, Joshua J., primary, Morgan, Todd M., primary, Wang, Yugang, primary, Levantini, Elena, primary, Clohessy, John G., primary, Kelly, Kathleen, primary, Pandolfi, Pier Paolo, primary, Rosenblatt, Jacalyn M., primary, Avigan, David E., primary, Ye, Huihui, primary, Karp, Jeffrey M., primary, Signoretti, Sabina, primary, Balk, Steven P., primary, and Cantley, Lewis C., primary

Published
2023
Full Text
View/download PDF

23. Supplementary Figure 3 from Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity

Author

Patnaik, Akash, primary, Swanson, Kenneth D., primary, Csizmadia, Eva, primary, Solanki, Aniruddh, primary, Landon-Brace, Natalie, primary, Gehring, Marina P., primary, Helenius, Katja, primary, Olson, Brian M., primary, Pyzer, Athalia R., primary, Wang, Lily C., primary, Elemento, Olivier, primary, Novak, Jesse, primary, Thornley, Thomas B., primary, Asara, John M., primary, Montaser, Laleh, primary, Timmons, Joshua J., primary, Morgan, Todd M., primary, Wang, Yugang, primary, Levantini, Elena, primary, Clohessy, John G., primary, Kelly, Kathleen, primary, Pandolfi, Pier Paolo, primary, Rosenblatt, Jacalyn M., primary, Avigan, David E., primary, Ye, Huihui, primary, Karp, Jeffrey M., primary, Signoretti, Sabina, primary, Balk, Steven P., primary, and Cantley, Lewis C., primary

Published
2023
Full Text
View/download PDF

24. Supplementary Figure 6 from Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity

Author

Patnaik, Akash, primary, Swanson, Kenneth D., primary, Csizmadia, Eva, primary, Solanki, Aniruddh, primary, Landon-Brace, Natalie, primary, Gehring, Marina P., primary, Helenius, Katja, primary, Olson, Brian M., primary, Pyzer, Athalia R., primary, Wang, Lily C., primary, Elemento, Olivier, primary, Novak, Jesse, primary, Thornley, Thomas B., primary, Asara, John M., primary, Montaser, Laleh, primary, Timmons, Joshua J., primary, Morgan, Todd M., primary, Wang, Yugang, primary, Levantini, Elena, primary, Clohessy, John G., primary, Kelly, Kathleen, primary, Pandolfi, Pier Paolo, primary, Rosenblatt, Jacalyn M., primary, Avigan, David E., primary, Ye, Huihui, primary, Karp, Jeffrey M., primary, Signoretti, Sabina, primary, Balk, Steven P., primary, and Cantley, Lewis C., primary

Published
2023
Full Text
View/download PDF

25. Supplementary Figure 2 from Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity

Author

Patnaik, Akash, primary, Swanson, Kenneth D., primary, Csizmadia, Eva, primary, Solanki, Aniruddh, primary, Landon-Brace, Natalie, primary, Gehring, Marina P., primary, Helenius, Katja, primary, Olson, Brian M., primary, Pyzer, Athalia R., primary, Wang, Lily C., primary, Elemento, Olivier, primary, Novak, Jesse, primary, Thornley, Thomas B., primary, Asara, John M., primary, Montaser, Laleh, primary, Timmons, Joshua J., primary, Morgan, Todd M., primary, Wang, Yugang, primary, Levantini, Elena, primary, Clohessy, John G., primary, Kelly, Kathleen, primary, Pandolfi, Pier Paolo, primary, Rosenblatt, Jacalyn M., primary, Avigan, David E., primary, Ye, Huihui, primary, Karp, Jeffrey M., primary, Signoretti, Sabina, primary, Balk, Steven P., primary, and Cantley, Lewis C., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Figure 7 from Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity

Author

Patnaik, Akash, primary, Swanson, Kenneth D., primary, Csizmadia, Eva, primary, Solanki, Aniruddh, primary, Landon-Brace, Natalie, primary, Gehring, Marina P., primary, Helenius, Katja, primary, Olson, Brian M., primary, Pyzer, Athalia R., primary, Wang, Lily C., primary, Elemento, Olivier, primary, Novak, Jesse, primary, Thornley, Thomas B., primary, Asara, John M., primary, Montaser, Laleh, primary, Timmons, Joshua J., primary, Morgan, Todd M., primary, Wang, Yugang, primary, Levantini, Elena, primary, Clohessy, John G., primary, Kelly, Kathleen, primary, Pandolfi, Pier Paolo, primary, Rosenblatt, Jacalyn M., primary, Avigan, David E., primary, Ye, Huihui, primary, Karp, Jeffrey M., primary, Signoretti, Sabina, primary, Balk, Steven P., primary, and Cantley, Lewis C., primary

Published
2023
Full Text
View/download PDF

27. Supplementary Figure 8 from Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity

Author

Patnaik, Akash, primary, Swanson, Kenneth D., primary, Csizmadia, Eva, primary, Solanki, Aniruddh, primary, Landon-Brace, Natalie, primary, Gehring, Marina P., primary, Helenius, Katja, primary, Olson, Brian M., primary, Pyzer, Athalia R., primary, Wang, Lily C., primary, Elemento, Olivier, primary, Novak, Jesse, primary, Thornley, Thomas B., primary, Asara, John M., primary, Montaser, Laleh, primary, Timmons, Joshua J., primary, Morgan, Todd M., primary, Wang, Yugang, primary, Levantini, Elena, primary, Clohessy, John G., primary, Kelly, Kathleen, primary, Pandolfi, Pier Paolo, primary, Rosenblatt, Jacalyn M., primary, Avigan, David E., primary, Ye, Huihui, primary, Karp, Jeffrey M., primary, Signoretti, Sabina, primary, Balk, Steven P., primary, and Cantley, Lewis C., primary

Published
2023
Full Text
View/download PDF

28. Supplementary Figure 4 from Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity

Author

Patnaik, Akash, primary, Swanson, Kenneth D., primary, Csizmadia, Eva, primary, Solanki, Aniruddh, primary, Landon-Brace, Natalie, primary, Gehring, Marina P., primary, Helenius, Katja, primary, Olson, Brian M., primary, Pyzer, Athalia R., primary, Wang, Lily C., primary, Elemento, Olivier, primary, Novak, Jesse, primary, Thornley, Thomas B., primary, Asara, John M., primary, Montaser, Laleh, primary, Timmons, Joshua J., primary, Morgan, Todd M., primary, Wang, Yugang, primary, Levantini, Elena, primary, Clohessy, John G., primary, Kelly, Kathleen, primary, Pandolfi, Pier Paolo, primary, Rosenblatt, Jacalyn M., primary, Avigan, David E., primary, Ye, Huihui, primary, Karp, Jeffrey M., primary, Signoretti, Sabina, primary, Balk, Steven P., primary, and Cantley, Lewis C., primary

Published
2023
Full Text
View/download PDF

29. Phase II clinical trial evaluating Abatacept in patients with steroid-refractory chronic graft versus host disease

Author

Koshy, Anita G., primary, Kim, Haesook T., additional, Liegel, Jessica, additional, Arnason, Jon E., additional, Ho, Vincent T., additional, Antin, Joseph H., additional, Joyce, Robin, additional, Cutler, Corey S., additional, Gooptu, Mahasweta, additional, Nikiforow, Sarah, additional, Logan, Emma K., additional, Elavalakanar, Pavania, additional, Narcis, Michele, additional, Stroopinsky, Dina, additional, Avigan, Zachary M., additional, Boussi, Leora, additional, Stephenson, Susan L, additional, El Banna, Hassan, additional, Bindal, Poorva, additional, Cheloni, Giulia, additional, Avigan, David E., additional, Soiffer, Robert J., additional, and Rosenblatt, Jacalyn, additional

Published
2023
Full Text
View/download PDF

30. Multivariable Analyses of Prognostic Factors for Progression-Free Survival (PFS) and Complete Response (CR) with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) and Lenalidomide (R) Maintenance to Progression in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

Author

Hassoun, Hani, primary, Jacobus, Susanna J, additional, Richardson, Paul G., additional, Zonder, Jeffrey, additional, Voorhees, Peter M., additional, Kaufman, Jonathan L., additional, Yee, Andrew J, additional, Scott, Emma C, additional, Torka, Pallawi, additional, Libby, Edward N., additional, Reeves, Brandi, additional, Wang, Michael L., additional, Anderson, Larry D., additional, Milner, Carter, additional, Gasparetto, Cristina, additional, Agha, Mounzer, additional, Khan, Dr. Abdullah, additional, Hurd, David D, additional, Avigan, David E., additional, Costello, Caitlin, additional, Jakubowiak, Andrzej, additional, Lonial, Sagar, additional, Raje, Noopur S, additional, Medvedova, Eva, additional, McCarthy, Dr. Philip L., additional, Orlowski, Robert Z., additional, Nadeem, Omar, additional, Laubach, Jacob, additional, Pasquini, Marcelo, additional, Giralt, Sergio, additional, Masone, Kelly, additional, Samur, Mehmet, additional, Perrot, Aurore, additional, Moreau, Philippe, additional, Avet-Loiseau, Hervé, additional, Weller, Edie, additional, Munshi, Nikhil C., additional, and Anderson, Kenneth C., additional

Published
2023
Full Text
View/download PDF

32. Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance‐conferring FLT3/tyrosine kinase domain/F691 mutation

Author

Fathi, Amir T., Blonquist, Traci M., Hernandez, Daniela, Amrein, Philip C., Ballen, Karen K., McMasters, Malgorzata, Avigan, David E., Joyce, Robin, Logan, Emma K., Hobbs, Gabriela, Brunner, Andrew M., Joseph, Christelle, Perry, Ashley M., Burke, Meghan, Behnan, Tanya, Foster, Julia, Bergeron, Meghan K., Moran, Jenna A., Ramos, Aura Y., Som, Tina T., Rae, Jessica, Fishman, Kaitlyn M., McGregor, Kristin L., Connolly, Christine, Neuberg, Donna S., and Levis, Mark J.

Published
2018
Full Text
View/download PDF

33. Synergism between CAR T Cells and a Personalized Tumor Vaccine in Hematological Malignances

Author

Cheloni, Giulia, primary, Capelletti, Marzia, additional, Torres, Daniela, additional, Bindal, Poorva, additional, Liegel, Jessica, additional, Stroopinsky, Dina, additional, Bisharat, Lina, additional, Rahimian, Maryam, additional, Yoo, Seo Yeon, additional, Hauser, Joshua, additional, Koshy, Anita G., additional, Dufort, Kenel, additional, Clohessy, John, additional, Kufe, Donald, additional, Themeli, Maria, additional, Sadelain, Michel, additional, Rosenblatt, Jacalyn, additional, and Avigan, David E., additional

Published
2022
Full Text
View/download PDF

34. Dendritic Cell/Multiple Myeloma (MM) Fusion Vaccine with Lenalidomide Maintenance after Autologous Hematopoietic Cell Transplant (HCT) Induces MM-Specific Immunity, BMT CTN 1401

Author

Chung, David J., primary, Shah, Nina, additional, Stroopinsky, Dina, additional, Wu, Juan (Maggie), additional, Bisharat, Lina, additional, Callander, Natalie S., additional, Logan, Brent, additional, Anderson, Kenneth C., additional, Dhakal, Binod, additional, Devine, Steven M., additional, Efebera, Yvonne, additional, Geller, Nancy, additional, Hematti, Peiman, additional, Holmberg, Leona A., additional, Howard, Alan, additional, Johnson, Bryon D, additional, Lazarus, Hillard M., additional, Malek, Ehsan, additional, McCarthy, Philip L., additional, McKenna, David H., additional, Mendizabal, Adam, additional, Munshi, Nikhil C., additional, O’Donnell, Lynn C., additional, Rapoport, Aaron P., additional, Nooka, Ajay, additional, Reese, Jane S, additional, Soiffer, Robert J., additional, Uhl, Lynne, additional, Cheloni, Giulia, additional, Karagkouni, Dimitra, additional, Vlachos, Ioannis, additional, Young, Jim, additional, Rosenblatt, Jacalyn, additional, Waller, Edmund K., additional, Pasquini, Marcelo C, additional, and Avigan, David E., additional

Published
2022
Full Text
View/download PDF

35. Phase II Clinical Trial of Abatacept for Steroid-Refractory Chronic Graft Versus Host Disease

Author

Koshy, Anita G., primary, Kim, Haesook, additional, Stroopinsky, Dina, additional, Liegel, Jessica, additional, Arnason, Jon E., additional, Ho, Vincent T., additional, Antin, Joseph H., additional, Joyce, Robin M., additional, Cutler, Corey, additional, Gooptu, Mahasweta, additional, Nikiforow, Sarah, additional, Logan, Emma, additional, Elavalakanar, Pavania, additional, Stephenson, Susan, additional, El Banna, Hassan, additional, Bindal, Poorva, additional, Cheloni, Giulia, additional, Avigan, David E., additional, Soiffer, Robert J., additional, and Rosenblatt, Jacalyn, additional

Published
2022
Full Text
View/download PDF

36. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

Author

Richardson, Paul G., Weller, Edie, Lonial, Sagar, Jakubowiak, Andrzej J., Jagannath, Sundar, Raje, Noopur S., Avigan, David E., Xie, Wanling, Ghobrial, Irene M., Schlossman, Robert L., Mazumder, Amitabha, Munshi, Nikhil C., Vesole, David H., Joyce, Robin, Kaufman, Jonathan L., Doss, Deborah, Warren, Diane L., Lunde, Laura E., Kaster, Sarah, DeLaney, Carol, Hideshima, Teru, Mitsiades, Constantine S., Knight, Robert, Esseltine, Dixie-Lee, and Anderson, Kenneth C.

Published
2010
Full Text
View/download PDF

37. Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease and Multiorgan Failure after Stem Cell Transplantation: A Multicenter, Randomized, Dose-Finding Trial

Author

Richardson, Paul G., Soiffer, Robert J., Antin, Joseph H., Uno, Hajime, Jin, Zhezhen, Kurtzberg, Joanne, Martin, Paul L., Steinbach, Gideon, Murray, Karen F., Vogelsang, Georgia B., Chen, Allen R., Krishnan, Amrita, Kernan, Nancy A., Avigan, David E., Spitzer, Thomas R., Shulman, Howard M., Di Salvo, Donald N., Revta, Carolyn, Warren, Diane, Momtaz, Parisa, Bradwin, Gary, Wei, L.J., Iacobelli, Massimo, McDonald, George B., and Guinan, Eva C.

Published
2010
Full Text
View/download PDF

41. CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma

Author

Madduri, Deepu, Berdeja, Jesus G., Usmani, Saad Z., Jakubowiak, Andrzej, Agha, Mounzer, Cohen, Adam D., Stewart, A. Keith, Hari, Parameswaran, Htut, Myo, O'Donnell, Elizabeth, Munshi, Nikhil C., Avigan, David E., Deol, Abhinav, Lesokhin, Alexander M., Singh, Indrajeet, Zudaire, Enrique, Yeh, Tzu-Min, Allred, Alicia J., Olyslager, Yunsi, Banerjee, Arnob, Goldberg, Jenna D., Schecter, Jordan M., Jackson, Carolyn C., Deraedt, William, Zhuang, Sen Hong, Infante, Jeffrey R., Geng, Dong, Wu, Xiaoling, Carrasco, Marlene J., Akram, Muhammad, Hossain, Farah, Rizvi, Syed, Fan, Frank, Jagannath, Sundar, Lin, Yi, and Martin, Thomas, III

Published
2020
Full Text
View/download PDF

42. Safety and Efficacy of Decitabine Plus Ipilimumab in Relapsed or Refractory MDS/AML in the Post-BMT or Transplant Naïve Settings

Author

Garcia, Jacqueline S., Flamand, Yael, Tomlinson, Benjamin K., Keng, Michael, Mendez, Lourdes M., Khaled, Samer, Bashey, Asad, Brunner, Andrew M., Savell, Alexandra, Neuberg, Donna, Galinsky, Ilene, Luskin, Marlise R., Steensma, David P., Wadleigh, Martha, Winer, Eric S., Avigan, David E., Cullen, Nicole, Rodig, Scott, Penter, Livius, Lindsley, R. Coleman, Andrews, Stephanie, Davids, Matthew S., Wu, Catherine J., Stone, Richard M., DeAngelo, Daniel J., and Soiffer, Robert J.

Published
2020
Full Text
View/download PDF

43. PML targeting eradicates quiescent leukaemia-initiating cells

Author

Ito, Keisuke, Bernardi, Rosa, Morotti, Alessandro, Matsuoka, Sahoko, Saglio, Giuseppe, Ikeda, Yasuo, Rosenblatt, Jacalyn, Avigan, David E., Teruya-Feldstein, Julie, and Pandolfi, Pier Paolo

Subjects
Gene therapy -- Research -- Health aspects -- Physiological aspects, Chronic myeloid leukemia -- Genetic aspects -- Development and progression -- Research, Tumor suppressor genes -- Health aspects -- Physiological aspects -- Research -- Genetic aspects, Cancer -- Care and treatment, Cancer cells -- Properties -- Genetic aspects -- Research -- Health aspects -- Physiological aspects, Oncogenes -- Physiological aspects -- Properties -- Health aspects -- Genetic aspects -- Research, Environmental issues, Science and technology, Zoology and wildlife conservation, Physiological aspects, Development and progression, Research, Genetic aspects, Properties, Health aspects
Abstract

The existence of a small population of 'cancer-initiating cells' responsible for tumour maintenance has been firmly demonstrated in leukaemia. This concept is currently being tested in solid tumours. Leukaemia-initiating cells, [...]

Published
2008

45. Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease

Author

Koreth, John, Matsuoka, Ken-ichi, Kim, Haesook T., McDonough, Sean M., Bindra, Bhavjot, Alyea, Edwin P., III, Armand, Philippe, Cutler, Corey, Ho, Vincent T., Treister, Nathaniel S., Bienfang, Don C., Prasad, Sashank, Tzachanis, Dmitrios, Joyce, Robin M., Avigan, David E., Antin, Joseph H., Ritz, Jerome, and Soiffer, Robert J.

Published
2011
Full Text
View/download PDF

46. Identification and Validation of CD138- Multiple Myeloma Immune and Tumor Subpopulations Using Cross Center Scrna-Seq Data

Author

Jayasinghe, Reyka G, primary, Yao, Lijun, additional, Thomas, Beena, additional, Bhasin, Swati S, additional, Fernandez, Nicolas, additional, Avigan, David E., additional, Kourelis, Taxiarchis, additional, Dhodapkar, Madhav V., additional, Vij, Ravi, additional, Mehr, Shaadi, additional, Hamilton, Mark, additional, Cho, Hearn Jay, additional, Auclair, Daniel, additional, Gnjatic, Sacha, additional, and Ding, Li, additional

Published
2020
Full Text
View/download PDF

47. Integrated Cytof, Scrna-Seq and Cite-Seq Analysis of Bone Marrow Immune Microenvironment in the Mmrf Commpass Study

Author

Yao, Lijun, primary, Jayasinghe, Reyka G, additional, Thomas, Beena E, additional, Bhasin, Swati S, additional, Fernandez, Nicolas, additional, Kourelis, Taxiarchis, additional, Doxie, Deon, additional, Avigan, David E., additional, Dhodapkar, Madhav V., additional, Kumar, Shaji K., additional, Vij, Ravi, additional, Mehr, Shaadi, additional, Hamilton, Mark, additional, Cho, Hearn Jay, additional, Auclair, Daniel, additional, Gnjatic, Sacha, additional, Bhasin, Manoj, additional, and Ding, Li, additional

Published
2020
Full Text
View/download PDF

48. Vaccination with a Personalized Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in a Phase 1 Clinical Trial

Author

Liegel, Jessica, primary, Stone, Richard M., additional, Soiffer, Robert J., additional, Stroopinsky, Dina, additional, Bisharat, Lina, additional, Rahimian, Maryam, additional, Logan, Emma, additional, Elavalakanar, Pavania, additional, Ho, Vincent T., additional, Romee, Rizwan, additional, Neuberg, Donna S., additional, Liu, Yiwen, additional, Mendez, Lourdes M., additional, Dias, Ajoy L., additional, Bindal, Poorva, additional, Koshy, Anita, additional, Orr, Shira, additional, Torres, Daniela, additional, Cheloni, Giulia, additional, Ebert, Benjamin L., additional, Kufe, Donald, additional, Avigan, David E., additional, and Rosenblatt, Jacalyn, additional

Published
2020
Full Text
View/download PDF

49. Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902

Author

Foss, Francine M., primary, Wang, Xin Victoria, additional, Luger, Selina M., additional, Jegede, Opeyemi, additional, Miller, Kenneth B., additional, Stadtmauer, Edward A., additional, Whiteside, Theresa L., additional, Avigan, David E., additional, Gascoyne, Randall D., additional, Arber, Daniel, additional, Wagner, Henry, additional, Strair, Roger K., additional, Hogan, William J., additional, Sprague, Kellie A., additional, Lazarus, Hillard M., additional, Litzow, Mark R., additional, Tallman, Martin S., additional, and Horning, Sandra J., additional

Published
2020
Full Text
View/download PDF

50. Development of Novel Second Generation DC/Tumor Fusion Vaccine in Lymphoma

Author

Orr, Shira, primary, Capelletti, Marzia, additional, Stroopinsky, Dina, additional, Liegel, Jessica, additional, Nahas, Myrna R., additional, Weinstock, Matthew, additional, Morin, Adam, additional, Joyce, Robin, additional, Jain, Salvia, additional, Arnason, Jon E., additional, Kufe, Donald, additional, Rosenblatt, Jacalyn, additional, and Avigan, David E., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results